跳转至内容
Merck

SML1832

Sigma-Aldrich

DDR1抑制剂7rh

≥98% (HPLC)

别名:

4-乙基-N-(3-((4-甲基哌嗪-1-基)甲基)-5-(三氟甲基)-苯基)-3-(吡唑并[1,5-a]嘧啶-6-基乙炔基)苯甲酰胺, 7rh

登录查看公司和协议定价


About This Item

经验公式(希尔记法):
C30H29F3N6O
分子量:
546.59
MDL號碼:
分類程式碼代碼:
12352200
NACRES:
NA.77

品質等級

化驗

≥98% (HPLC)

形狀

powder

顏色

white to beige

溶解度

DMSO: 10 mg/mL, clear

儲存溫度

2-8°C

SMILES 字串

O=C(NC1=CC(C(F)(F)F)=CC(CN2CCN(C)CC2)=C1)C3=CC=C(CC)C(C#CC4=CN5C(N=C4)=CC=N5)=C3

一般說明

DDR1抑制剂7rh是针对盘状结构域受体-1(DDR1)的强效激酶小分子抑制剂。可抑制鼻咽癌(NPC)细胞的成瘤性。DDR1抑制剂7rh抑制癌细胞的增殖、侵袭和粘附。

生化/生理作用

DDR1抑制剂7rh是一种口服并具有ATP竞争性的有效DDR1选择性抑制剂,具有体外体内的抗癌作用。
化合物7rh是一种针对含有盘菌素结构域的受体1(DDR1; IC50 = 6.8 nM, [ATP] = 100 nM)的高效、高亲和力(kd =0.6 nM)ATP竞争性抑制剂,对于包括DDR2、Bcr-abl和c-Kit(分别的IC50 = 101.4 nM, 355 nM和>10 μM)在内的其它455种激酶具有显著减低的作用。抑制剂7rh可以剂量依赖性的方式降低DDR1的表达/磷酸化以及下游的信号传导(0.1-2 μM; NCI-H23 NSCLCs)、有效抑制人类癌细胞增殖(IC50从38 nM/K562降至2.98 μM/NCI-H460)和克隆形成(IC50 = 0.56 μM/NCI-H23)。抑制剂7rh可在大鼠和小鼠中进行口服(T1/2 = 15.53 h;Tmax = 4.25 h; Cmax = 1867.5μg/L,F = 67.4%; 25mg/kg;大鼠)并在小鼠(50mg/kg/天 p.o.)中显示出对Kras(LSLG12Vgeo)肿瘤生长的体内功效。

儲存類別代碼

11 - Combustible Solids

水污染物質分類(WGK)

WGK 3

閃點(°F)

Not applicable

閃點(°C)

Not applicable


分析证书(COA)

输入产品批号来搜索 分析证书(COA) 。批号可以在产品标签上"批“ (Lot或Batch)字后找到。

已有该产品?

在文件库中查找您最近购买产品的文档。

访问文档库

Chiara Ambrogio et al.
Nature medicine, 22(3), 270-277 (2016-02-09)
Patients with advanced Kirsten rat sarcoma viral oncogene homolog (KRAS)-mutant lung adenocarcinoma are currently treated with standard chemotherapy because of a lack of efficacious targeted therapies. We reasoned that the identification of mediators of Kras signaling in early mouse lung
Antitumor activity of 7RH, a discoidin domain receptor 1 inhibitor, alone or in combination with dasatinib exhibits antitumor effects in nasopharyngeal carcinoma cells
Lu QP, et al.
Oncology Letters, 12(5), 3598-3608 (2016)
Mingshan Gao et al.
Journal of medicinal chemistry, 56(8), 3281-3295 (2013-03-26)
Discoidin domain receptor 1 (DDR1) is an emerging potential molecular target for new anticancer drug discovery. We have discovered a series of 3-(2-(pyrazolo[1,5-a]pyrimidin-6-yl) ethynyl)benzamides that are selective and orally bioavailable DDR1 inhibitors. The two most promising compounds (7rh and 7rj)
Protein Analysis and Purification: Benchtop Techniques, 3598-3608 (2018)
Hoon Hur et al.
BMC cancer, 17(1), 87-87 (2017-02-02)
Discoidin domain receptor 1 (DDR1), a receptor tyrosine kinase that utilizes collagen as a ligand, is a key molecule in the progression of solid tumors as it regulates the interaction of cancer cells with the tumor stroma. However, the clinical

我们的科学家团队拥有各种研究领域经验,包括生命科学、材料科学、化学合成、色谱、分析及许多其他领域.

联系技术服务部门